Luveris-75

Luveris-75 Uses, Dosage, Side Effects, Food Interaction and all others data.

Luveris-75 is a recombinant human luteinizing hormone produced in yeast with 2 subunits, alpha = 92 residues, beta = 121 residues. It is a heterodimeric glycoprotein made up of monomeric units. Luveris-75 was the first and only recombinant human form of luteinizing hormone (LH) developed for use in the stimulation of follicular development. Its pharmacological action mimics the biological activity of endogenous LH; an acute rise of LH, or LH surge, in females triggers ovulation and the development of the corpous luteum. In males, LH stimulates Leydig cell to produce testosterone.

Used to facilitate female conception, lutropin alfa performs the same actions as luteinizing hormone (LH), which is normally produced in the pituitary gland. Lutropin is usually given in combination with follitropin alfa. Together they stimulate the development of a follicle to prepare the reproductive tract for implementation and pregnancy. Luveris-75 also stimulates the theca cells to produce androgens and the secretion of estradiol by the follicles. Luveris-75 and follitropin alfa are discontinued once ultrasound assessment and serum estradiol concentrations show sufficient follicular maturation. hCG is then administered to complete follicular maturation and induce ovulation. In females, a LH surge about halfway through the menstrual cycle triggers the onset of ovulation. Luveris-75 substitutes for endogenous LH and induces rupture of the preovulatory ovarian follicle and oocyte expulsion. Luveris-75 induces and maintains the corpus luteum, which then secretes progesterone.

Luveris-75
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Luveris-75
Generic	Lutropin alfa
Lutropin alfa Other Names	Lutropin alfa, Lutropin alpha, Lutropina alfa
Type
Formula	C₁₀₁₄H₁₆₀₉N₂₈₇O₂₉₄S₂₇
Weight	30000.0 Da
Groups	Approved
Therapeutic Class
Manufacturer
Available Country	Turkey
Last Updated:	September 19, 2023 at 7:00 am

Uses

Luveris-75 is a form of recombinant human luteinizing hormone used to treat female infertility due to hypothalamic or pituitary insufficiency, or due to profound luteinizing hormone deficiency.

For treatment of infertility in women with hypothalamic or pituitary insufficiency (hypogonadotropic hypogonadism) and profound LH deficiency (LH <1.2 international units [IU]/L)

Luveris-75 is also used to associated treatment for these conditions: Hypogonadism, Infertility

How Luveris-75 works

Luteinizing hormone binds to a receptor shared with the human chorionic gonadotropin hormone (hCG) on the ovarian theca (and granulosa) cells and testicular Leydig cells. This LH/CG transmembrane receptor is a member of the super-family of G protein-coupled receptors. Adenylate cyclase then activates many other pathways leading to steroid hormone production and other follicle maturation processes.

Toxicity

Luveris-75 is not indicated for people under 16 and over 60, pregnant and lactating women, patients with uncontrolled thyroid and adrenal failure, patients with active, untreated tumours of the hypothalamus and pituitary gland, and in any patient with a condition that makes a normal pregnancy possible such as primary ovarian failure or fibroid tumors of the uterus.

Food Interaction

No interactions found.

Volume of Distribution

The steady state volume of distribution is around 10-14 L.

Elimination Route

Mean absolute bioavailability is 56%, following sub-Q administration, maximum serum concentrations reached after 4–16 hours. Time to peak, serum: 9 hours